CALGARY, Alberta--(BUSINESS WIRE)--April 16, 2004--Mr. W. Scott Lawler, sole member of the Board of Directors, is pleased to announce the following:
Acrongenomics Inc. has agreed to acquire four patents, as well as all intellectual property associated with such patents, from Dr. Leftheris Georgakopoulos, a Greek scientist. The patents cover highly predictive, metastic cancer molecular diagnostic test products, including the EP-CAM Detection Kit(TM) that Dr. Georgakopoulos has developed for commercialization. The Company will issue 4,000,000 shares of its common stock for these patents and associated intellectual property to Dr. Georgakopoulos.
The appointment of Dr. Leftheris Georgakopoulos, 37, as President and Chief Scientific Officer of Acrongenomics Inc., as well as appointment to the Board of Directors of Acrongeonomics Inc.
Dr. Leftheris Georgakopoulos studied Molecular Biology and Genetics in the Karl - Ruprecht University of Heidelberg, Germany. He finished his doctoral thesis in the Medical School of Karl - Ruprecht University of Heidelberg and then continued as a post-doctoral fellow. He is author of more than thirty-five published presentations and publications and he is an inventor of four patents. He worked with the clinical application of Molecular Biology as well as with the conduction of programs in diseases and cancer. He drew up, supervised and executed programs in hepatitis B and cancer of epithelial origin. In particular he focused on the micrometastatic disease in epithelial cancers where he was issued two patents for EP - CAM detection that led to the EP-CAM Detection Kit(TM) for the detection of the micrometastatic disease, the first product of Acrongenomics Inc. Furthermore he is the inventor of two more patents one for RNA isolation procedure, and one for the detection of Human Hepatitis B virus. His work has been rewarded by international scientific congresses and meetings, and awarded by various Institutions. He is member of the New York Academy of Science, American Association for the Advancement of Science, European Association of Biochemistry and Greek Association of Molecular Biology.
The appointment of Mr. R.W. (Rick) Walchuk, 47, as CEO and member of the Board of Directors of Acrongenomics Inc.
Mr. Rick Walchuk attended the University of Saskatchewan, College of Commerce, Saskatoon Campus and for the past twenty-four years was in investment advisor with various Canadian brokerage firms. Mr Walchuk will bring an extensive background in all aspects of venture capital, investor relations and corporate governance.
Mr. W. Scott Lawler will remain as a member of the Board of Directors and the company’s legal counsel.
Contacts
Acrongenomics Inc. Director/Legal Counsel: W. Scott Lawler, 403-693-8014 wslawler@isgsecurities.com
